ESTRO 2024 - Abstract Book

S211

Brachytherapy - Gynaecology

ESTRO 2024

Conclusion:

Combined intracavitary and interstitial brachytherapy using tandem/ring + needle applicator allows appropriate target coverage in tumors with residual medial parametrial involvement post EBRT , for equivalent doses to OARS in comparison to standard ICBT. Based on the positive preliminary experience with better HRCTV coverage and local control, this technique should be used more liberally in this subgroup of patients with unfavorable target volumes.

Keywords: Medial parametrial disease, IC/ISBT

References:

1.https://www.estro.org/Congresses/ESTRO2022/672/brachytherapygynaecology/10153/impactofovoidsizeinintr a-cavitarybrachytherapyupon

2. Kirisits C, Lang S, Dimopoulos J, et al. The Vienna applicator for combined intracavitary and interstitial brachytherapy of cervical cancer: Design, application, treatment planning, and dosimetric results. Int J Radiat Oncol Biol Phys.65(2006):624-630

3.ICRU Report 38, Dose and Volume Specification for Reporting Intracavitary Therapy in Gynecology

198

Digital Poster

Single-insertion with four sessions high dose rate brachytherapy for advanced cervical cancer

Lucie Houdou 1 , Claire Meynard 1 , Sophie Guillerm 1 , Camille Mimoun 2 , Tiphaine Lambert 3 , Eva Marchand 2 , Diane Jornet 1 , Ingrid Fumagalli 1 , Laurent Quero 1 , Cyrille Huchon 4 , Christophe Hennequin 1 1 Saint-Louis Hospital, Radiation Oncology Department, Paris, France. 2 Lariboisière Hospital, Gynecologic Department, Paris, France. 3 Saint-Louis Hospital, Medical Oncology Department, Paris, France. 4 4- University of Paris-Cité, Cancer Institute of Oncology, Paris, France

Purpose/Objective:

This study aims to assess the feasibility and efficacy of high-dose-rate (HDR) brachytherapy (BT) administered in a single insertion with four treatment sessions for locally advanced cervical cancer (LACC), and to identify the prognostic factors influencing outcomes.

Material/Methods:

We retrospectively analyzed the clinical data of cervical cancer patients with locally advanced disease (International Federation of Gynecology and Obstetrics 2018 (FIGO) IB-IVB), treated at our institution from January 2014 through December 2021. Each patient received definitive radiotherapy with an external irradiation dosage